Crucell Inks Deal with Sanofi Pasteur for Next-Generation Biologicals Against Rabies
Crucell N.V. (Leiden, the Netherlands) has signed an exclusive collaboration and commercialization agreement with Sanofi Pasteur (Lyon, France) for Crucell’s rabies monoclonal antibodies, the next-generation rabies biologicals to be used in association with rabies vaccine for post-exposure prophylaxis against this fatal disease.
Crucell N.V. (Leiden, the Netherlands) has signed an exclusive collaboration and commercialization agreement with Sanofi Pasteur (Lyon, France) for Crucell’s rabies monoclonal antibodies, the next-generation rabies biologicals to be used in association with rabies vaccine for post-exposure prophylaxis against this fatal disease.
Under the terms of the agreement, Crucell will continue to perform the development activities, be responsible for the manufacturing of the final product, and retain exclusive distribution rights in Europe, co-exclusive distribution rights in China, and the rights to sell to supranational organizations such as UNICEF. Crucell will receive a payment of €10 million following the execution of the agreement and will be eligible for milestone payments of up to €66.5 million.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
